Pulmonary veno-occlusive disease in Sjogren's syndrome: a case report
Authors:
Open Access
- 18 January 2023
- journal article
- case report
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 23 (1) , 1-6
Abstract
Background: Pulmonary arterial hypertension (PAH) associated with connective tissue disease (CTD) belongs to Group 1 pulmonary hypertension. Pulmonary veno-occlusive disease (PVOD), which is characterized by venous system aberrations, has been previously reported in CTD-PAH; however, it has rarely been observed in Sjogren’s syndrome (SS). Case presentation: Our 28-year-old female patient was admitted to the hospital with recurrent shortness of breath even after minimal physical activity. Her chest high-resolution CT scan demonstrated pulmonary artery dilatation and bilateral ground-glass nodules. A subsequent right heart catheterization confirmed pulmonary hypertension because her mean pulmonary arterial pressure was 62 mmHg. Our inquisitive genomic assessment identified a novel EIF2AK4 mutation at c.1021 C > T (p. Gln341*), the dominant causal gene of PVOD. Histological examination demonstrated stenosis and occlusions in the pulmonary veins. Because she presented with features such as dry eyes and Raynaud's phenomenon, we performed a biopsy on the labial salivary gland, which confirmed SS. Her treatment regimen included PAH-targeted therapies (tadalafil and macitentan) in combination with hydroxychloroquine. Although she was hospitalized several times due to acute exacerbation of PAH, her disease progression was under control, and she did not demonstrate any signs of pulmonary edema even after a three-year treatment period. Conclusion: Here, we report the case of an SS-PAH patient with PVOD who carried a novel biallelic EIF2AK4 mutation, and PAH-targeted therapies were well tolerated by our patient.Keywords
Funding Information
- National Natural Science Foundation of China (81873416, 82070055, 8210012237)
- Key Research and Development Program of Hunan Province (2020SK2065)
- Fundamental Research Funds for the Central Universities of Central South University (1053320191678)
- VUMC Faculty Research Scholars grant
- Natural Science Foundation Project of Hunan Province (2020JJ4634)
This publication has 28 references indexed in Scilit:
- A founder EIF2AK4 mutation causes an aggressive form of pulmonary arterial hypertension in Iberian GypsiesClinical Genetics, 2014
- Keeping the eIF2 alpha kinase Gcn2 in checkBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2014
- Survival in systemic sclerosis-associated pulmonary arterial hypertension in the modern management eraAnnals of the Rheumatic Diseases, 2013
- EIF2AK4 mutations cause pulmonary veno-occlusive disease, a recessive form of pulmonary hypertensionNature Genetics, 2013
- Survival and Prognostic Factors in Systemic Sclerosis–Associated Pulmonary Hypertension: A Systematic Review and Meta‐AnalysisArthritis & Rheumatism, 2013
- Pulmonary hypertension in rheumatic diseases: epidemiology and pathogenesisRheumatology International, 2013
- Pulmonary veno-occlusive diseaseEuropean Respiratory Journal, 2008
- Pulmonary veno-occlusive disease as a primary cause of pulmonary hypertension in a patient with mixed connective tissue diseaseRheumatology International, 2007
- Structural Basis for Autoinhibition and Mutational Activation of Eukaryotic Initiation Factor 2α Protein Kinase GCN2*[boxs]Journal of Biological Chemistry, 2005
- Characterization of a mammalian homolog of the GCN2 eukaryotic initiation factor 2α kinaseEuropean Journal of Biochemistry, 1999